Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2

Recurring chromosomal aberrations are of aetiological, diagnostic, prognostic and therapeutic importance in acute myeloid leukaemia (AML). However, aberrations are detected in only two thirds of AML cases at diagnosis and recurrent balanced translocations in only 50%. Spectral karyotyping (SKY) enables simultaneous visualization of all human chromosomes in different colours, facilitating the comprehensive evaluation of chromosomal abnormalities. Therefore, SKY was used to characterize 37 cases of newly diagnosed AML‐M2, previously analysed using G‐banding. In 15/23 patients it was possible to obtain metaphases from viably frozen cells; in 22 additional cases, fixed‐cell suspensions were used. Of the 70 chromosomal aberrations identified by SKY, 30 aberrations were detected for the first time, 18 aberrations were redefined and 22 were confirmed. SKY detected two reciprocal translocations, t(X;3) and t(11;19). In five cases, eight structural aberrations resulted in partial gains of chromosome 21, six of which were undetected by G‐banding. In 4/5 cases, these resulted in copy number increases for AML1. Amplification of MYC was detected in three cases. Using SKY and FISH, clonal aberrations were identified in 5/18 cases with a presumed normal karyotype; 3/5 aberrations were of known unfavourable prognostic significance. Karyotypes were entered into a custom‐designed SKY database, which will be integrated with other cytogenetic and genomic databases.

[1]  O. Haas,et al.  Felix Mitelman: Database of chromosome aberrations in cancer , 2002, Human Genetics.

[2]  M. Slovak,et al.  Twenty‐four‐color spectral karyotyping reveals chromosome aberrations in cytogenetically normal acute myeloid leukemia , 2000, Genes, chromosomes & cancer.

[3]  H. Scherthan,et al.  Double minutes and c-MYC amplification in acute myelogenous leukemia: Are they prognostic factors? , 2000, Cancer genetics and cytogenetics.

[4]  Alex E. Lash,et al.  A systematic, high-resolution linkage of the cytogenetic and physical maps of the human genome , 2000, Nature Genetics.

[5]  S. Hiebert,et al.  Role of the transcription factor AML-1 in acute leukemia and hematopoietic differentiation. , 2000, Gene.

[6]  James R. Downing,et al.  Expression of the AML-1 Oncogene Shortens the G1Phase of the Cell Cycle* , 2000, The Journal of Biological Chemistry.

[7]  S. Glaser,et al.  Acute Myeloid Leukemia , 2020, New England Journal of Medicine.

[8]  N. Kakazu,et al.  Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome , 1999, Genes, chromosomes & cancer.

[9]  A. Friedman.  Leukemogenesis by CBF oncoproteins , 1999, Leukemia.

[10]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  L. Chan,et al.  Trisomy 21 as the sole acquired karyotypic abnormality in acute myeloid leukemia and myelodysplastic syndrome. , 1999, Leukemia research.

[12]  J. Rowley.  The role of chromosome translocations in leukemogenesis. , 1999, Seminars in hematology.

[13]  C. Morris,et al.  Identification of amplified genes in a patient with acute myeloid leukemia and double minute chromosomes. , 1999, Cancer genetics and cytogenetics.

[14]  W. Hiddemann,et al.  Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. , 1999, Blood.

[15]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[16]  G. Evans,et al.  Molecular cytogenetics localizes two new breakpoints on 11q23.3 and 21q11.2 in myelodysplastic syndrome with t(11;21) translocation , 1999, Genes, chromosomes & cancer.

[17]  M. Seto,et al.  Amplification on double‐minute chromosomes and partial‐tandem duplication of the MILL gene in leukemic cells of a patient with acute myelogenous leukemia , 1998, Genes, chromosomes & cancer.

[18]  A T Look,et al.  Oncogenic transcription factors in the human acute leukemias. , 1997, Science.

[19]  N. Zhao,et al.  dic(5;17): A recurring abnormality in malignant myeloid disorders associated with mutations of TP53 , 1997, Genes, chromosomes & cancer.

[20]  T. Veldman,et al.  Spectral karyotyping, a 24-colour FISH technique for the identification of chromosomal rearrangements , 1997, Histochemistry and Cell Biology.

[21]  B. Johansson,et al.  A breakpoint map of recurrent chromosomal rearrangements in human neoplasia , 1997, Nature Genetics.

[22]  Thomas Ried,et al.  Hidden chromosome abnormalities in haematological malignancies detected by multicolour spectral karyotyping , 1997, Nature Genetics.

[23]  T. Haferlach,et al.  Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. , 1996, Leukemia.

[24]  D. Ledbetter,et al.  Multicolor Spectral Karyotyping of Human Chromosomes , 1996, Science.

[25]  D. Ward,et al.  Karyotyping human chromosomes by combinatorial multi-fluor FISH , 1996, Nature Genetics.

[26]  K. Tanaka,et al.  Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies. , 1996, Oncogene.

[27]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[28]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[29]  P. Jacobs,et al.  Cytogenetic and molecular studies of Down syndrome individuals with leukemia. , 1995, American journal of human genetics.

[30]  A. Hagemeijer,et al.  Interphase cytogenetics of the t(8;21)(q22;q22) associated with acute myelogenous leukemia by two-color fluorescence in situ hybridization. , 1995, Cancer genetics and cytogenetics.

[31]  R. Berger,et al.  t( 12;21): A new recurrent translocation in acute lymphoblastic leukemia , 1994, Genes, chromosomes & cancer.

[32]  P. Pelicci,et al.  Mapping of chromosome 17 breakpoints in acute myeloid leukemias. , 1990, Oncogene.

[33]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[34]  J. Westin,et al.  Cytogenetic studies of bone marrow and extramedullary tissues and clinical course during metamorphosis of chronic myelocytic leukemia. , 1983, Cancer genetics and cytogenetics.

[35]  M. Bernard,et al.  Jumping translocation in acute leukemia of myelomonocytic lineage: a case report and review of the literature , 2000, Leukemia.

[36]  U. Jäger,et al.  Amplification of the MLL gene on double minutes, a homogeneously staining region, and ring chromosomes in five patients with acute myeloid leukemia or myelodysplastic syndrome. , 2000, Genes, chromosomes & cancer.

[37]  大里 元美.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2 α B gene associated with myeloblastic leukemias , 1999 .

[38]  E. Estey,et al.  Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. , 1995, Leukemia.